phospholipid syndrome

phos·pho·lip·id syn·drome

the combination of antiphospholipid antibodies and the presence of either arterial or venous occlusive events such as thrombosis.
References in periodicals archive ?
Pathophysiology of the anti phospholipid syndrome [Review].
Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the anti phospholipid syndrome [Review].
Guidelines on the investigation and management of the anti phospholipid syndrome.
Increased levels of [beta] glycoprotein-I antigen and [beta]glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary anti phospholipid syndrome.
Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and the anti phospholipid syndrome.
Reactivity to [beta]2 glycoprotein I clearly differentiates anticardiolipin antibodies from anti phospholipid syndrome and syphilis.
Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary anti phospholipid syndrome.
International consensus statement on preliminary classification criteria for definite anti phospholipid syndrome.
Clinical manifestations of the anti phospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycopro tein-I than with anti phospholipid antibodies.